Breast cancer-specific survival (BCSS) in patients (pts) with node-negative (N0) and node-positive (N plus ) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

Winer E. P.; Shak S.; Sledge G. W. Jr.; Albain K. S.; Mamounas E. P.; Jakubowski D. M.; Petkov V. I.; Wolmark N.; Hortobagyi G. N.

首页> 外文期刊>The Breast : >Breast cancer-specific survival (BCSS) in patients (pts) with node-negative (N0) and node-positive (N plus ) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

【24h】

Breast cancer-specific survival (BCSS) in patients (pts) with node-negative (N0) and node-positive (N plus ) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

机译：患者（PTS）的乳腺癌特异性存活（BCSS）与节点阴性（N0）和Node阳性（N加）乳腺癌（BC）引导的21-Gene测定：Seer-Genomic现实世界的证据研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《The Breast :》 |2019年第1期|共2页
作者
Winer E. P.; Shak S.; Sledge G. W. Jr.; Albain K. S.; Mamounas E. P.; Jakubowski D. M.; Petkov V. I.; Wolmark N.; Hortobagyi G. N.;
展开▼
作者单位

Dana Farber Canc Inst Boston MA 02115 USA;

Genom Hlth Inc Redwood City CA USA;

Stanford Univ Stanford CA 94305 USA;

Loyola Univ Chicago Cardinal Bernardin Canc Ctr Maywood IL USA;

Orlando Hlth UF Hlth Canc Ctr Orlando FL USA;

Genom Hlth Inc Redwood City CA USA;

NCI Bethesda MD 20892 USA;

NSABP Fdn Pittsburgh PA USA;

Univ Texas MD Anderson Canc Ctr Houston TX 77030 USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类胸部外科学;
关键词

相似文献

外文文献
中文文献
专利

1. Breast cancer-specific survival (BCSS) in patients (pts) with node-negative (N0) and node-positive (N plus ) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study [J] . Winer E. P., Shak S., Sledge G. W. Jr., The Breast : . 2019,第期

机译：患者（PTS）的乳腺癌特异性存活（BCSS）与节点阴性（N0）和Node阳性（N加）乳腺癌（BC）引导的21-Gene测定：Seer-Genomic现实世界的证据研究
2. Breast cancer-specific mortality (BCSM) in patients age 50 years or younger with node-positive (N plus ) breast cancer (BC) treated based on the 21-gene assay in clinical practice [J] . Intelligence: A Multidisciplinary Journal . 2020,第期

机译：乳腺癌特异性死亡率（BCSM）50岁或以下患者患者阳性阳性（N加）乳腺癌（BC）基于临床实践的21-基因测定治疗
3. Breast cancer-specific survival in 6,768 patients with lymph nodepositive (LN plus ) hormone receptor-positive (HR plus ) invasive breast cancer (BC) and 21-gene Recurrence Score (R) (RS) results in the SEER registries [J] . Shak S., Roberts M., Petkov V. I., The Breast : . 2017,第期

机译：6,768名淋巴结患者的乳腺癌癌细胞存活率（LN Plus）激素受体阳性（HR加）侵入性乳腺癌（BC）和21-基因复发评分（R）（RS）导致SEER注册表
4. Breast MRI radiomics for the pre-treatment prediction of response to neoadjuvant chemotherapy in node-positive breast cancer patients [C] . Karen Drukker, Iman El-Bawab, Alexandra Edwards, SPIE Conference on Computer-Aided Diagnosis . 2019

机译：乳腺MRI辐射射清，用于节点阳性乳腺癌患者对新辅助化疗的反应预处理预测
5. Economic evaluation of 21-gene assay for early stage breast cancer patients from the perspective of the Chinese health care system. [D] . Zhou, Mi. 2012

机译：从中国卫生保健系统的角度对早期乳腺癌患者进行21基因检测的经济评价。
6. The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use [O] . W. Eiermann, M. Rezai, S. Kümmel, -1

机译：21个基因的复发评分分析影响了ER阳性淋巴结阴性和淋巴结阳性的早期乳腺癌的辅助治疗建议从而导致化疗的风险适应性改变
7. Prospective Study of the Effect of the 21-Gene Assay on Adjuvant Clinical Decision-Making in Japanese Women With Estrogen Receptor-Positive, Node-Negative, and Node-Positive Breast Cancer [O] . Yamauchi Hideko, Nakagawa Chizuko, Takei Hiroyuki, 2014

机译：21基因检测对日本雌激素受体阳性，淋巴结阴性和淋巴结阳性乳腺癌女性辅助临床决策的影响的前瞻性研究

Breast cancer-specific survival (BCSS) in patients (pts) with node-negative (N0) and node-positive (N plus ) breast cancer (BC) guided by the 21-gene assay: a SEER-genomic real-world evidence study

著录项

相似文献

相关主题

期刊订阅